RUNX1T1 and acute myeloid leukemia: In accordance with the ELN 2022 guidelines, persistent detectable MRD in RUNX1::RUNX1T1-positive AML generally necessitates treatment escalation and consideration of allo-HSCT in eligible patients (1).